Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) to a sell rating in a research note released on Monday.

Several other research firms have also commented on NTLA. Canaccord Genuity Group reiterated a “buy” rating and set a $90.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Citigroup increased their price target on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Morgan Stanley lowered Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Oppenheimer decreased their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Finally, William Blair reiterated a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $9.36 on Monday. The business’s 50 day simple moving average is $10.69 and its 200-day simple moving average is $15.32. Intellia Therapeutics has a 1 year low of $8.30 and a 1 year high of $32.00. The stock has a market capitalization of $968.92 million, a price-to-earnings ratio of -1.72 and a beta of 1.97.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 29,000 shares of company stock worth $352,551. Insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NTLA. ARK Investment Management LLC grew its position in shares of Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock worth $146,174,000 after buying an additional 280,946 shares in the last quarter. Vanguard Group Inc. grew its holdings in Intellia Therapeutics by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock worth $118,816,000 after acquiring an additional 562,249 shares in the last quarter. State Street Corp grew its holdings in Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in Intellia Therapeutics during the 4th quarter valued at about $43,177,000. Finally, Geode Capital Management LLC raised its holdings in shares of Intellia Therapeutics by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock valued at $27,865,000 after purchasing an additional 45,930 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.